Next-gen Cologuard test demonstrates 94% sensitivity & 91% specificity for CRC

Labcorp and Alliance partner to support multi-institution trial to expand genetic testing in CRC

Labcorp and the Alliance for Clinical Trials in Oncology will collaborate on a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer.

June 05, 2026

Vol.52 No.22

Drugs & Targets

FDA grants Fast Track designation to Suplexa in MSI-H CRC

FDA granted Fast Track designation to Suplexa, a differentiated, non-engineered autologous treatment, for the treatment of patients with colorectal cancer of the MSI-H phenotype.

May 15, 2026

Vol.52 No.19

Clinical Trials & Tribulations

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

The incidence of multiple cancer types in people under the age of 50 has been rising, with early-onset cancers now contributing to nearly 15,000 excess cases of cancer in the U.S. annually.

March 27, 2026

Vol.52 No.12

By W. Kimryn Rathmell

Trials & Tribulations

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.

March 27, 2026

Vol.52 No.12

By Richard M. Goldberg

Clinical

Colorectal cancer is now the leading cause of cancer death in patients under 50
Why aren’t 45-year-olds getting their recommended CRC screenings?

Three decades ago, colorectal cancer was the fifth leading cause of cancer death in patients under 50 years old. For a physician treating the average 45-year-old, colorectal cancer was not a diagnosis that immediately came to mind.

March 27, 2026

Vol.52 No.12

By Sara Willa Ernst

Early-onset colorectal cancer demands a new research playbook

Colorectal cancer is no longer a disease confined to older adults.

March 20, 2026

Vol.52 No.11

By Marwan Fakih

Next-gen Cologuard test demonstrates 94% sensitivity & 91% specificity for CRC

YOU MAY BE INTERESTED IN

Labcorp and Alliance partner to support multi-institution trial to expand genetic testing in CRC

FDA grants Fast Track designation to Suplexa in MSI-H CRC

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

Colorectal cancer is now the leading cause of cancer death in patients under 50
Why aren’t 45-year-olds getting their recommended CRC screenings?

Early-onset colorectal cancer demands a new research playbook

Renew today!

Subscriber content

Never miss an issue!

Login

Next-gen Cologuard test demonstrates 94% sensitivity & 91% specificity for CRC

YOU MAY BE INTERESTED IN

Labcorp and Alliance partner to support multi-institution trial to expand genetic testing in CRC

FDA grants Fast Track designation to Suplexa in MSI-H CRC

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

In the era of immunotherapy, response rate alone fails to predict true patient benefitRegulators must adapt

Colorectal cancer is now the leading cause of cancer death in patients under 50Why aren’t 45-year-olds getting their recommended CRC screenings?

Early-onset colorectal cancer demands a new research playbook

Never miss an issue!

Login

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

Colorectal cancer is now the leading cause of cancer death in patients under 50
Why aren’t 45-year-olds getting their recommended CRC screenings?